Kunihiko Miyazaki1, Shinya Sato2, Takahide Kodama2, Takeshi Numata3, Takeo Endo3, Yusuke Yamamoto4, Kei Shimizu4, Hideyasu Yamada5, Kenji Hayashihara6, Shinichiro Okauchi7, Hiroaki Satoh7, Yutaka Yamada8, Tomohiro Tamura8, Kazuto Saito9, Norihiro Kikuchi10, Koichi Kurishima11, Hiroichi Ishikawa11, Hiroko Watanabe12, Toshihiro Shiozawa13, Nobuyuki Hizawa13, Yasunori Funayama14, Shigen Hayashi15, Hiroyuki Nakamura16, Takaaki Yamashita17. 1. Division of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan k.miyazaki@ryugasaki-hp.org. 2. Division of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan. 3. Division of Respiratory Medicine, Mito Medical Center, Mito, Japan. 4. Division of Respiratory Medicine, Hitachi General Hospital, Hitachi, Japan. 5. Division of Respiratory Medicine, Hitachinaka General Hospital-Hitachinaka Medical Center, University of Tsukuba, Hitachinaka, Japan. 6. Division of Respiratory Medicine, Ibarakihigashi Hospital, Tokai, Japan. 7. Divisions of Respiratory Medicine and Thoracic Surgery, Mito Kyodo General Hospital-Mito Medical Center, University of Tsukuba, Mito, Japan. 8. Respiratory Center, Ibaraki Prefectural Central Hospital, Kasama, Japan. 9. Division of Thoracic Surgery, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan. 10. Division of Respiratory Medicine, Kasumigaura Medical Center Hospital, Tsuchiura, Japan. 11. Division of Respiratory Medicine, Tsukuba Medical Center Hospital, Tsukuba, Japan. 12. Division of Respiratory Medicine, Tsukuba Kinen Hospital, Tsukuba, Japan. 13. Faculty of Clinical Medicine, University of Tsukuba, Tsukuba, Japan. 14. Division of Respiratory Medicine Tsukuba, Gakuen General Hospital, Tsukuba, Japan. 15. Division of Respiratory Medicine, Ibaraki Seinan Medical Center Hospital, Sakai, Japan. 16. Division of Respiratory Medicine, Tokyo Medical University, Ibaraki Medical Center, Ami-machi, Japan. 17. Division of Respiratory Medicine, JA Toride Medical Center Hospital, Toride, Japan.
Abstract
AIM: To clarify the clinicopathological features in elderly anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: A retrospective study was performed in 129 ALK rearranged NSCLC patients diagnosed between April 2008 and March 2019 in fifteen Institutions of the Ibaraki prefecture, Japan. RESULTS: Median age of patients was 63 years. In 59 patients aged 65 and older, the proportions of patients with advanced stage and those treated with ALK-tyrosine kinase inhibitor (TKI) were lower than those younger than 65 years. There was no difference in overall survival (OS) between the two age groups. Among the elderly patients, no difference was observed in OS between the patients aged 65-69 and those aged 70 and older. In 89 patients treated with TKI, no significant differences were observed in the progression-free survival of TKIs and OS between patients aged 65 and older and those younger than 65, respectively. CONCLUSION: Evaluation of ALK gene status and TKI treatment are desirable even for elderly patients. Copyright
AIM: To clarify the clinicopathological features in elderly anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: A retrospective study was performed in 129 ALK rearranged NSCLCpatients diagnosed between April 2008 and March 2019 in fifteen Institutions of the Ibaraki prefecture, Japan. RESULTS: Median age of patients was 63 years. In 59 patients aged 65 and older, the proportions of patients with advanced stage and those treated with ALK-tyrosine kinase inhibitor (TKI) were lower than those younger than 65 years. There was no difference in overall survival (OS) between the two age groups. Among the elderly patients, no difference was observed in OS between the patients aged 65-69 and those aged 70 and older. In 89 patients treated with TKI, no significant differences were observed in the progression-free survival of TKIs and OS between patients aged 65 and older and those younger than 65, respectively. CONCLUSION: Evaluation of ALK gene status and TKI treatment are desirable even for elderly patients. Copyright
Authors: Alona Zer; Mor Moskovitz; David M Hwang; Anat Hershko-Klement; Ludmila Fridel; Grzegorz J Korpanty; Elizabeth Dudnik; Nir Peled; Tzippy Shochat; Natasha B Leighl; Geoffrey Liu; Ronald Feld; Ronald Burkes; Mira Wollner; Ming-Sound Tsao; Frances A Shepherd Journal: Clin Lung Cancer Date: 2016-10-26 Impact factor: 4.785